Want to see HK:6872 full AI Analyst Report?
6872 Stock Chart & Stats
$125.00
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$115.60 - $287.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)79.47K
Market Cap
HK$6.54B
Enterprise Value$10.69K
Total Cash (Recent Filing)HK$183.76M
Total Debt (Recent Filing)HK$28.65M
Price to Earnings (P/E)―
Beta-0.13
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding52,328,926
10 Day Avg. Volume97,808
30 Day Avg. Volume79,472
Financial Highlights & Ratios
PEG Ratio-12.90
Price to Book (P/B)63.75
Price to Sales (P/S)0.00
P/FCF Ratio-111.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Modest LeverageModest leverage provides a stronger financial base than a highly indebted balance sheet and may reduce near-term pressure from debt servicing. The 2025 debt-to-equity position gives management greater flexibility to fund development while limiting the balance-sheet amplification of operating losses.
Positive Equity PositionReturning to positive shareholders’ equity is a meaningful structural improvement in solvency relative to the prior two years. Although accumulated losses remain a concern, the improved capital position offers more protection for creditors and creates a stronger foundation for continued development spending.
2024 Loss And Burn ImprovementThe improvement in 2024 operating cash burn and net loss shows that the company has demonstrated some ability to reduce spending pressure from the 2023 level. This offers evidence of potential cost-control capacity, although the reversal in 2025 means the improvement has not yet proven durable.
Bears Say
No Commercial RevenueA three-year absence of reported revenue indicates that commercial traction has not yet been established. Without product sales or operating revenue, the company remains dependent on capital resources to support development, making future financial progress highly dependent on achieving successful commercialization.
Persistent Large LossesLarge recurring net losses show that the current business is not yet economically self-sustaining. The slight worsening in 2025 after improvement in 2024 suggests limited evidence of a lasting narrowing trend, leaving earnings power dependent on future progress rather than existing operations.
Negative Cash GenerationConsistently negative operating and free cash flow means reported losses are translating into substantial cash outflows. The renewed increase in burn during 2025 raises the need for continued funding and reduces financial flexibility if development spending remains high without revenue generation.
TenNor Therapeutics Suzhou Ltd. Class H News
6872 FAQ
What was TenNor Therapeutics Suzhou Ltd. Class H’s price range in the past 12 months?
TenNor Therapeutics Suzhou Ltd. Class H lowest stock price was $115.60 and its highest was $287.00 in the past 12 months.
What is TenNor Therapeutics Suzhou Ltd. Class H’s market cap?
TenNor Therapeutics Suzhou Ltd. Class H’s market cap is HK$6.54B.
When is TenNor Therapeutics Suzhou Ltd. Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were TenNor Therapeutics Suzhou Ltd. Class H’s earnings last quarter?
Currently, no data Available
Is TenNor Therapeutics Suzhou Ltd. Class H overvalued?
According to Wall Street analysts TenNor Therapeutics Suzhou Ltd. Class H’s price is currently Undervalued.
Does TenNor Therapeutics Suzhou Ltd. Class H pay dividends?
TenNor Therapeutics Suzhou Ltd. Class H does not currently pay dividends.
What is TenNor Therapeutics Suzhou Ltd. Class H’s EPS estimate?
TenNor Therapeutics Suzhou Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TenNor Therapeutics Suzhou Ltd. Class H have?
TenNor Therapeutics Suzhou Ltd. Class H has 52,328,926 shares outstanding.
What happened to TenNor Therapeutics Suzhou Ltd. Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of TenNor Therapeutics Suzhou Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6872
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TenNor Therapeutics Suzhou Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
Company Description
TenNor Therapeutics Suzhou Ltd. Class H
TenNor Therapeutics (Suzhou) Limited specializes in researching, developing, and bringing to market unique therapies for illnesses arising from bacterial infections and bacterial metabolic functions. Its robust product pipeline includes Rifasutenizole (TNP-2198), designed to combat Helicobacter pylori infections. Another key asset, Rifaquizinone (TNP-2092), is being advanced in an injectable formulation to treat Periprosthetic Joint Infection (PJI), Acute Bacterial Skin and Skin Structure Infections (ABSSSI), and infections associated with Left Ventricular Assist Devices (LVADs). An oral variant of TNP-2092 is aimed at addressing conditions linked to gut bacterial metabolism, such as Hepatic Encephalopathy (HE) and Irritable Bowel Syndrome with Diarrhea (IBS-D). Furthermore, their development programs feature a topical TNP-2092 for confronting drug-resistant bacterial strains and biofilm-mediated infections; TNBi-1, a novel narrow-spectrum small molecule for H. pylori; TNBi-2, a broad-spectrum, multi-targeting small molecule for Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD); and TNBm-1, a broad-spectrum bifunctional small molecule for metabolic disorders. The company was established in 2012 and maintains its headquarters in Suzhou, China.
Technical Analysis
Zai Lab Ltd
―
InnoCare Pharma Ltd.
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
Ascentage Pharma Group International
―
Mabwell (Shanghai) Bioscience Co., Ltd. Class H
―